Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

not_yet_recruiting2100%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_3

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

NCT07286331
not_yet_recruitingphase_3

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

NCT07286266

Clinical Trials (2)

Showing 2 of 2 trials
NCT07286331Phase 3

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Not Yet Recruiting
NCT07286266Phase 3

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2